China NKST

NKST (Guangdong NKST Biotechnology) is a clinical-stage biopharmaceutical company based in China that specializes in the development of innovative Natural Killer (NK) cell therapies for oncology. The company leverages its proprietary 'eNK' platform to engineer enhanced NK cells with improved persistence, infiltration, and tumor-killing capabilities. Their pipeline includes both non-modified and chimeric antigen receptor (CAR)-modified NK cell products targeting a variety of solid tumors and hematological cancers. NKST aims to provide off-the-shelf, safe, and effective cellular immunotherapies to address significant unmet medical needs in the global cancer landscape.